Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
ROPINIROLE (ROPINIROLE HYDROCHLORIDE)
SANIS HEALTH INC
N04BC04
ROPINIROLE
0.25MG
TABLET
ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 0.25MG
ORAL
100
Prescription
NONERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS
Active ingredient group (AIG) number: 0132618001; AHFS:
APPROVED
2010-06-18
_ _ _ROPINIROLE 0.25 mg, 1 mg, Tablets _ _Page 1 of 53_ PRODUCT MONOGRAPH Pr ROPINIROLE Ropinirole Tablets, USP 0.25 mg and 1 mg ropinirole (as ropinirole hydrochloride) Antiparkinsonian Agent / Dopamine Agonist Sanis Health Inc. 1 President’s Choice Circle Brampton, Ontario L6Y 5S5 Date of Revision: February 10, 2021 Submission Control No.: 244016 _ _ _ROPINIROLE 0.25 mg, 1 mg Tablets _ _Page 2 of 53_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 9 DRUG INTERACTIONS ................................................................................................. 21 DOSAGE AND ADMINISTRATION ............................................................................. 23 OVERDOSAGE ............................................................................................................... 24 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 25 STORAGE AND STABILITY ......................................................................................... 29 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 29 PART II: SCIENTIFIC INFORMATION .............................................................................. 30 PHARMACEUTICAL INFORMATION ......................................................................... 30 CLINICAL TRIALS ............................................................................... Prečítajte si celý dokument